JP2004516811A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004516811A5 JP2004516811A5 JP2002504279A JP2002504279A JP2004516811A5 JP 2004516811 A5 JP2004516811 A5 JP 2004516811A5 JP 2002504279 A JP2002504279 A JP 2002504279A JP 2002504279 A JP2002504279 A JP 2002504279A JP 2004516811 A5 JP2004516811 A5 JP 2004516811A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- peptide conjugate
- amino acid
- group
- conjugate according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000863 peptide conjugate Substances 0.000 description 27
- 108090000765 processed proteins & peptides Proteins 0.000 description 26
- 238000000034 method Methods 0.000 description 17
- 125000000539 amino acid group Chemical group 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000013543 active substance Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 206010021036 Hyponatraemia Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 2
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 229940088623 biologically active substance Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- -1 fatty acid amines Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 239000002171 loop diuretic Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- RAVVEEJGALCVIN-AGVBWZICSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RAVVEEJGALCVIN-AGVBWZICSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 102400001111 Nociceptin Human genes 0.000 description 1
- 108090000622 Nociceptin Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000036525 aquaresis Effects 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- PULGYDLMFSFVBL-SMFNREODSA-N nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200000944 | 2000-06-16 | ||
| DKPA200001485 | 2000-10-05 | ||
| US25167100P | 2000-12-06 | 2000-12-06 | |
| PCT/US2001/019113 WO2001098324A1 (en) | 2000-06-16 | 2001-06-15 | Peptide conjugates modified n- and/or c-terminally by short charged peptide chains |
| PCT/US2001/041008 WO2002028412A1 (en) | 2000-10-05 | 2001-06-15 | Novel use of peptide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004516811A JP2004516811A (ja) | 2004-06-10 |
| JP2004516811A5 true JP2004516811A5 (enExample) | 2007-01-25 |
| JP4624639B2 JP4624639B2 (ja) | 2011-02-02 |
Family
ID=27222400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002504279A Expired - Fee Related JP4624639B2 (ja) | 2000-06-16 | 2001-06-15 | 短い荷電ペプチド鎖によってｎ及び／又はｃ末端が修飾されたペプチド |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1294746B1 (enExample) |
| JP (1) | JP4624639B2 (enExample) |
| AT (1) | ATE508138T1 (enExample) |
| AU (1) | AU7294401A (enExample) |
| CA (1) | CA2410224C (enExample) |
| CY (1) | CY1111740T1 (enExample) |
| DE (1) | DE60144561D1 (enExample) |
| WO (1) | WO2001098324A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550425B2 (en) | 2000-06-16 | 2009-06-23 | Zealand Pharma A/S | Diuretic peptide conjugates |
| US7244701B2 (en) | 2000-06-16 | 2007-07-17 | Zealand Phama A/S | Diuretic peptide conjugate |
| WO2003030828A2 (en) | 2001-10-09 | 2003-04-17 | Synvax, Inc. | Nociceptin-based analgesics |
| WO2003097857A2 (en) * | 2002-05-17 | 2003-11-27 | Zealand Pharma A/S | Method for the detection of aquaretic compounds |
| US7790681B2 (en) | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
| JP2006514649A (ja) * | 2003-12-17 | 2006-05-11 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 腎症の治療および予防のための組成物 |
| WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| CA2807036C (en) | 2010-10-14 | 2018-01-16 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
| WO2012065082A1 (en) * | 2010-11-11 | 2012-05-18 | Massachusetts Institute Of Technology | Dendrimer-based excipients for the attentuation of protein aggregation |
| WO2013091670A1 (en) * | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
| WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| AU2014301631A1 (en) | 2013-06-26 | 2015-08-27 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
| WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| EP3065757A4 (en) | 2013-10-09 | 2017-08-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
| CN103936838B (zh) * | 2014-04-10 | 2015-10-28 | 武汉启瑞科技发展有限公司 | 小分子多肽TAT-p53DM及其在制备治疗或预防缺血性卒中药物中的应用 |
| GB201506380D0 (en) | 2015-04-15 | 2015-05-27 | Serodus Asa | Materials and methods for treatment of pulmonary hypertension |
| CA3209741A1 (en) * | 2021-02-26 | 2022-09-01 | Shohei Koide | Compositions and methods comprising antibodies that bind to covalent peptide conjugates |
| WO2025037992A1 (en) * | 2023-08-13 | 2025-02-20 | Filip Majewski | New peptides and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5814603A (en) * | 1992-06-12 | 1998-09-29 | Affymax Technologies N.V. | Compounds with PTH activity |
| AU2712999A (en) * | 1998-03-05 | 1999-09-20 | Novo Nordisk A/S | Use of hexapeptides for the manufacture of a pharmaceutical composition for the treatment of hot flushes |
| EP1950224A3 (en) * | 1998-03-09 | 2008-12-17 | Zealand Pharma A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| CN1254234C (zh) * | 2000-06-09 | 2006-05-03 | 莱古伦公司 | 质粒dna(lipogenestm)和含细胞核定位信号/促融合肽缀合物的治疗剂包封到定向脂质体复合体中 |
| US7459539B2 (en) * | 2000-12-15 | 2008-12-02 | Agensys, Inc. | Antibody that binds zinc transporter protein 108P5H8 |
-
2001
- 2001-06-15 DE DE60144561T patent/DE60144561D1/de not_active Expired - Lifetime
- 2001-06-15 EP EP01952155A patent/EP1294746B1/en not_active Expired - Lifetime
- 2001-06-15 AU AU7294401A patent/AU7294401A/xx active Pending
- 2001-06-15 JP JP2002504279A patent/JP4624639B2/ja not_active Expired - Fee Related
- 2001-06-15 WO PCT/US2001/019113 patent/WO2001098324A1/en not_active Ceased
- 2001-06-15 CA CA2410224A patent/CA2410224C/en not_active Expired - Fee Related
- 2001-06-15 AT AT01952155T patent/ATE508138T1/de active
-
2011
- 2011-07-28 CY CY20111100737T patent/CY1111740T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004516811A5 (enExample) | ||
| CN107075574A (zh) | 铁调素和微型铁调素类似物及其用途 | |
| JP2005120094A5 (enExample) | ||
| JP2514518B2 (ja) | ヘプタペプチドおよびオクタペプチドのソマトスタチン類似アミド誘導体、それを含有する抗腫瘍剤 | |
| CA3073806A1 (en) | Opioid agonist peptides and uses thereof | |
| JPH03504013A (ja) | Ｔ細胞ヘルパー活性を有するペプチド | |
| AU2368899A (en) | New peptide compounds that are analogues of the glucagon-like peptide-1 (7-37), a process for their preparation and pharmaceutical compositions containing them | |
| KR20140100937A (ko) | 펩티도미메틱 거대고리 | |
| CN105579467A (zh) | 用于治疗炎性疾病和/或免疫疾病的皮质抑素类似物 | |
| CN102532301A (zh) | 一类新型的Exendin-4类似物及其制备方法 | |
| EP0646127B1 (en) | Polypeptide bombesin antagonists | |
| AU2004232314B2 (en) | Peptide vectors | |
| AU6751290A (en) | Synthetic calcitonin peptides | |
| JPS59139347A (ja) | Ｇｒｆ類似体 | |
| CN102089329B (zh) | 抑制hiv感染的多肽及其衍生物 | |
| EP4617282A1 (en) | Membrane fusion inhibitor for inhibiting aids virus and drug-resistant strain thereof, and pharmaceutical use thereof | |
| JPS61191698A (ja) | 新規な環状ヘキサペプチドｌｈｒｈ拮抗剤 | |
| US5079231A (en) | Immunostimulating peptides, a process for their preparation and pharmaceutical compositions containing them | |
| US5786335A (en) | Sulfhydryl containing peptides for treating vascular disease | |
| EP0018182A1 (en) | Peptides having thymopoietin-like activity, therapeutic compositions containing them, and process for their preparation | |
| WO2001062777A1 (en) | Bombesin analogs for treatment of cancer | |
| JPH09501913A (ja) | Ｌｈｒｈのｎ末端改変類似体 | |
| KR20070083815A (ko) | 고체상 합성에서 ｓ-알킬-술페닐 보호기 | |
| EP1198478B1 (en) | Somatostatin analogs and their use for the treatment of cancer | |
| JP2010150253A (ja) | 肝癌を治療するための薬剤 |